Depakote for Bipolar Disorder: How It Works and Side Effects

Depakote is one of the more widely prescribed medications in bipolar disorder, and also one of the more frequently misunderstood.

Many people starting Depakote (divalproex sodium) know it is a mood stabilizer and that it can help with mania. Far fewer know what it cannot do, what its black box warnings mean in practical terms, and what the monitoring it requires actually involves. That gap creates avoidable problems: patients who stop Depakote unexpectedly, patients on it who do not know they should not become pregnant, patients whose dose is too low to do anything useful.

This guide covers what Depakote actually does in the brain, what it is and is not approved for, its real side effect profile, and what competent ongoing management of Depakote looks like.

What This Page Covers

• What Depakote is and how it works neurobiologically
• Its FDA-approved uses in bipolar disorder and what it does not treat
• The three black box warnings and what they mean
• The most common and most clinically significant side effects
• Drug monitoring requirements and what the numbers mean
• Who should not take Depakote
• How Depakote compares to lithium as a mood stabilizer

What Depakote Is

Depakote is the brand name for divalproex sodium, a formulation of valproic acid (VPA). Valproic acid is classified as an anticonvulsant, originally developed to treat epilepsy. Its mood-stabilizing effects were discovered later, and it is now one of the most commonly prescribed medications for bipolar mania.

Divalproex sodium is approved for acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features, according to FDA labeling for Depakote ER.

Depakote comes in three main formulations:

• Depakote DR (delayed release tablets, typically twice daily)
• Depakote ER (extended release tablets, typically once daily)
• Depakote Sprinkle Capsules (delayed release, can be mixed with food)

Depakote ER is often preferred in clinical practice because once-daily dosing supports adherence and the extended-release formulation tends to produce fewer GI side effects than the immediate-release version.

How Depakote Works in Bipolar Disorder

The exact mechanism by which valproate stabilizes mood is not fully understood, but three main biological effects are well-established.

GABA enhancement. Depakote’s mechanism of action is thought to be related to how it impacts gamma-aminobutyric acid (GABA), a neurotransmitter linked to calming and inhibitory effects in the brain. GABA is the brain’s primary inhibitory neurotransmitter. By increasing GABA activity, Depakote reduces excessive neuronal excitability.

Sodium channel blockade. Depakote blocks voltage-gated sodium channels, suppressing the high-frequency repetitive neuronal firing that drives manic episodes.

Glutamate modulation. Some evidence suggests valproate also reduces glutamate, the brain’s primary excitatory neurotransmitter, further contributing to its stabilizing effect.

The therapeutic uses of valproic acid include epilepsy treatment, bipolar disorder management, and migraine prophylaxis. The mechanism involves enhancement of inhibitory neurotransmission and modulation of voltage-gated ion channels, according to the NCBI StatPearls review of valproic acid.

What Depakote Is and Is Not Approved For

This is where many patients receive incomplete information.

Depakote IS FDA-approved for:

• Acute manic episodes in bipolar disorder (Depakote DR)
• Acute manic or mixed episodes in bipolar disorder (Depakote ER)
• Epilepsy (complex partial seizures, absence seizures)
• Migraine prophylaxis in adults

Depakote IS NOT FDA-approved for:

• Bipolar depression
• Maintenance treatment of bipolar disorder

Valproate is not approved for the treatment of bipolar depression or as a maintenance treatment. Valproate also does not have FDA approval as a maintenance treatment for bipolar disorder. Its use for that purpose, although common, is off-label, according to a Psychiatric Times review by a Harvard Medical School associate professor of psychiatry.

This is clinically important. Many patients on Depakote long-term for bipolar disorder maintenance are being treated off-label, and if they also experience bipolar depression, Depakote may not be addressing the depressive episodes. Your prescriber should have discussed this with you and, if needed, added a medication with evidence specifically for the depressive phase.

The Three Black Box Warnings

Depakote carries three FDA black box warnings, the highest level of safety alert on a drug label.

1. Hepatotoxicity (liver damage). Liver failure resulting in death has occurred in patients taking valproate. The risk is highest during the first six months of treatment, per the current FDA prescribing information. Children under 2 and people with certain mitochondrial disorders (POLG mutations) are at highest risk. For most adults, the risk is low but requires active monitoring. Symptoms of liver problems include nausea, vomiting, abdominal pain, dark urine, and yellowing of the eyes or skin. These require immediate contact with your prescriber.

2. Pancreatitis. Valproate has been associated with life-threatening pancreatitis in both children and adults. It can occur at any point during treatment, even after years on the medication. Severe abdominal pain, nausea, and vomiting are warning signs.

3. Fetal harm. Depakote can cause serious birth defects and neurodevelopmental effects in children exposed in utero, including neural tube defects (such as spina bifida), heart malformations, and lower IQ scores. The risk is dose-dependent. For women of childbearing potential, effective contraception is essential during treatment. The FDA labeling states that for epilepsy or bipolar disorder, Depakote should only be used in pregnant women if other treatments have failed to provide adequate control.

Side Effect Profile: What to Expect

Common side effects (manageable in most patients):

• Nausea and GI upset: Very common at initiation. Often improved by taking with food, switching to Depakote ER, or dividing the daily dose. Usually improves after 2 to 4 months of treatment.
• Weight gain: A dose-related effect that can be clinically significant for some patients. Dietary monitoring and regular check-ins with your prescriber are appropriate.
• Tremor: A fine tremor, particularly of the hands. Dose-related and often manageable with dose reduction. Propranolol is sometimes used if tremor is bothersome.
• Hair thinning: Occurs in a subset of patients, particularly at higher doses. Often reversible with dose reduction or discontinuation. Some patients benefit from supplementing with zinc and selenium, though evidence is limited.
• Sedation: Particularly at higher doses or with concurrent CNS medications.

Serious side effects requiring prompt contact with your prescriber:

• Signs of liver problems: jaundice, dark urine, upper right abdominal pain
• Signs of pancreatitis: severe abdominal pain, vomiting
• Thrombocytopenia (low platelet count): unusual bruising or bleeding
• Hyperammonemia: confusion, unusual sleepiness, particularly if combined with topiramate

Drug Level Monitoring: What the Numbers Mean

Depakote requires regular blood monitoring to confirm therapeutic levels and check for toxicity.

Serum drug levels should be monitored, with therapeutic ranges set at 50 to 100 mcg/mL for epilepsy and 50 to 125 mcg/mL for mania, according to the StatPearls pharmacology review. Toxic levels are indicated above 175 mcg/mL on a trough sample.

Monitoring should include:

• Liver function tests (LFTs) at baseline and at regular intervals during the first 6 months and periodically thereafter
• Complete blood count (CBC) to monitor platelet levels
• Valproate serum trough levels to confirm the dose is in the therapeutic range
• Ammonia levels if behavioral or cognitive changes occur

Missing blood work is not just an administrative inconvenience. For Depakote specifically, it is part of safe medication management.

Depakote vs. Lithium for Bipolar Disorder

Both Depakote and lithium are first-line treatments for acute bipolar mania. Choosing between them requires a clinical conversation that considers side effect profile, other medical conditions, pregnancy status, and individual history.

Key differences in practice:

• Efficacy: Lithium has a stronger evidence base for relapse prevention and long-term maintenance. Depakote’s maintenance use is primarily supported by open-label studies.
• Side effects: Both cause GI issues at initiation. Lithium requires renal monitoring and carries a narrower therapeutic index. Depakote requires hepatic monitoring and carries greater teratogenic risk.
• Special populations: Depakote may be preferred over lithium for mixed mania and some presentations with rapid cycling. Lithium may be preferred for patients planning pregnancy (with appropriate management), given the relative teratogenic risks.

About SiggyMD

Bipolar disorder frequently co-occurs with significant anxiety and depression. Managing those co-occurring conditions, under consistent clinical oversight, changes the daily baseline and can make the fluctuations of bipolar disorder more navigable.

“Bipolar disorder is not a single condition: it’s a complex system of mania, depression, and the spaces between,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Many people with bipolar disorder also live with significant anxiety and recurrent depression. Managing those co-occurring conditions with the right medication and with daily monitoring data changes how quickly clinicians can respond when something shifts. Waiting for a quarterly appointment to find out the dose stopped working is not how good bipolar care functions.”

SiggyMD provides clinician-supervised SSRI management for anxiety and depression, with daily check-ins that build a longitudinal picture of how medication is actually affecting daily life. For bipolar-specific mood stabilizer management, a psychiatrist with bipolar disorder expertise is the appropriate primary clinical resource. For the anxiety and depression that frequently accompany bipolar disorder, SiggyMD provides continuous, clinician-reviewed care.

No name, no email, no account required to start. A licensed prescriber reviews every treatment plan.

For more on bipolar disorder and mood stabilizers, see our guides on Lamictal for bipolar, mood stabilizers for bipolar disorder, and bipolar 1 vs 2.

Start your anonymous intake with SiggyMD.

What Members Are Saying

TK

T.K., 36

Bipolar I, Started Depakote After Lithium Intolerance

“I couldn’t tolerate lithium’s impact on my kidneys. My psychiatrist explained Depakote as an alternative with a different monitoring profile. What I didn’t expect was how much the regular blood work would catch early. My levels were too high at one point, and we adjusted before I had any real problems. The monitoring was more important than I initially thought.”

SL

S.L., 29

Bipolar II, Depakote for Mania Management

“The weight gain was real and nobody told me how significant it could be. When I finally asked my prescriber about it, we reduced the dose slightly and the trajectory changed. I wish someone had been tracking my weight consistently from the start. That’s the kind of thing daily check-ins would have caught much earlier.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Sources

1. U.S. Food and Drug Administration. Depakote ER Prescribing Information. AbbVie Inc. 2018.

2. U.S. Food and Drug Administration. Depakote (divalproex sodium) Prescribing Information. AbbVie Inc. 2026.

3. Bhatt M, et al. Valproic Acid. StatPearls. NCBI Bookshelf. Updated 2023.

4. National Institute of Mental Health. Bipolar Disorder. NIMH. Reviewed 2024.

5. Macritchie K, et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database of Systematic Reviews. 2003.

6. Bhatt M, et al. Valproate in Psychiatry: Approved Indications and Off-Label Uses. Psychopharmacology Institute. 2015.

7. Osser DN. Valproic Acid: Overused in Bipolar Disorder? Psychiatric Times. 2020.

8. University of Florida Department of Psychiatry. Medications for OCD — Valproate Section. UF College of Medicine. Accessed June 2026.